BRPI1011540A2 - anticorpos anticxcr4 para o tratamento de of hiv - Google Patents

anticorpos anticxcr4 para o tratamento de of hiv

Info

Publication number
BRPI1011540A2
BRPI1011540A2 BRPI1011540-4A BRPI1011540A BRPI1011540A2 BR PI1011540 A2 BRPI1011540 A2 BR PI1011540A2 BR PI1011540 A BRPI1011540 A BR PI1011540A BR PI1011540 A2 BRPI1011540 A2 BR PI1011540A2
Authority
BR
Brazil
Prior art keywords
antibodies
hiv
treatment
anticxcr4
cxcr4
Prior art date
Application number
BRPI1011540-4A
Other languages
English (en)
Inventor
Klinguer-Hamour Christine
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011540(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of BRPI1011540A2 publication Critical patent/BRPI1011540A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"anticorpos anticxcr4 para o tratamento de of hiv". a presente invenção se refere a novos anticorpos isolados, ou 5 os compostos derivados ou fragmentos funcionais dos mesmos, capazes de se ligarem a cxcr4, mas também de induzir mudanças conformacionais dos homodímeros de cxcr4 e capazes de inibirem replicação isolada primária de hiv-1 em pbmc. mais particularmente, a presente invenção se refere aos anticorpos monoclonais 515h7 e 301 ae5, específicos para a pro- 10 teína cxcr4, bem como seu uso para o tratamento de infecção de hiv. composições farmacêuticas compostas de tais anticorpos e um processo para a seleção de tais anticorpos são também cobertos.
BRPI1011540-4A 2009-04-29 2010-04-29 anticorpos anticxcr4 para o tratamento de of hiv BRPI1011540A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17368009P 2009-04-29 2009-04-29
EP09159076.0 2009-04-29
EP09159076A EP2246364A1 (en) 2009-04-29 2009-04-29 Anti CXCR4 antibodies for the treatment of HIV
US61/173,680 2009-04-29
PCT/EP2010/055863 WO2010125162A1 (en) 2009-04-29 2010-04-29 Anti cxcr4 antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
BRPI1011540A2 true BRPI1011540A2 (pt) 2019-04-30

Family

ID=41060014

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1011540-4A BRPI1011540A2 (pt) 2009-04-29 2010-04-29 anticorpos anticxcr4 para o tratamento de of hiv
BR112013009984A BR112013009984A2 (pt) 2009-04-29 2011-10-27 anticorpos para tratamento do hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013009984A BR112013009984A2 (pt) 2009-04-29 2011-10-27 anticorpos para tratamento do hiv

Country Status (26)

Country Link
US (3) US9090686B2 (pt)
EP (2) EP2246364A1 (pt)
JP (1) JP5800802B2 (pt)
KR (1) KR20120039525A (pt)
CN (1) CN102459343B (pt)
AU (1) AU2010243526B2 (pt)
BR (2) BRPI1011540A2 (pt)
CA (1) CA2759989A1 (pt)
CL (1) CL2011002664A1 (pt)
CO (1) CO6390114A2 (pt)
ES (1) ES2534313T3 (pt)
GE (1) GEP20146181B (pt)
HK (1) HK1165813A1 (pt)
HU (1) HUE025083T2 (pt)
IL (1) IL215919A0 (pt)
MA (1) MA33285B1 (pt)
MX (1) MX2011011285A (pt)
MY (1) MY155400A (pt)
NZ (1) NZ596712A (pt)
PL (1) PL2424897T3 (pt)
RU (1) RU2573902C2 (pt)
SG (1) SG175353A1 (pt)
TN (1) TN2011000534A1 (pt)
UA (1) UA107929C2 (pt)
WO (1) WO2010125162A1 (pt)
ZA (1) ZA201108330B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Hivの治療用抗体
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
CN106102837B (zh) 2013-12-02 2020-10-13 艾伦戴蒙德艾滋病研究中心 双特异性hiv-1-中和抗体
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
KR102165120B1 (ko) 2015-12-15 2020-10-13 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스 중화 항체
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR20220129044A (ko) * 2020-01-16 2022-09-22 카이로스 테라퓨틱스 인코포레이티드 골수종 및 난소암 세포에 특이적인 인간화 항체
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル-マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0512112B1 (en) * 1990-11-27 1997-05-28 Biogen, Inc. Anti cd-4 antibodies blocking hiv-induced syncytia
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5844094A (en) * 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
AU1834197A (en) * 1996-01-30 1997-08-22 National Institutes Of Health, The Cells expressing both human cd4 and cxcr4
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2005010153A2 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
BRPI0717512A2 (pt) * 2006-09-29 2013-11-19 Hoffmann La Roche Anticorpos contra ccr5 e usos dos mesmos
CN101951953A (zh) * 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
AU2010318542B2 (en) * 2009-10-29 2015-08-27 Janssen Biotech Inc. Antibody glycosylation variants
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
WO2010125162A1 (en) 2010-11-04
US20110088104A1 (en) 2011-04-14
ES2534313T3 (es) 2015-04-21
RU2573902C2 (ru) 2016-01-27
ZA201108330B (en) 2012-09-26
US9090686B2 (en) 2015-07-28
SG175353A1 (en) 2011-11-28
IL215919A0 (en) 2011-12-29
CN102459343A (zh) 2012-05-16
CO6390114A2 (es) 2012-02-29
JP2012525129A (ja) 2012-10-22
PL2424897T3 (pl) 2015-07-31
BR112013009984A2 (pt) 2017-07-18
UA107929C2 (en) 2015-03-10
JP5800802B2 (ja) 2015-10-28
CA2759989A1 (en) 2010-11-04
RU2011148077A (ru) 2013-06-10
MX2011011285A (es) 2012-01-20
MA33285B1 (fr) 2012-05-02
KR20120039525A (ko) 2012-04-25
EP2246364A1 (en) 2010-11-03
CN102459343B (zh) 2015-09-16
EP2424897A1 (en) 2012-03-07
HK1165813A1 (en) 2012-10-12
AU2010243526B2 (en) 2015-02-12
GEP20146181B (en) 2014-10-27
HUE025083T2 (en) 2016-02-29
TN2011000534A1 (en) 2013-05-24
MY155400A (en) 2015-10-15
AU2010243526A1 (en) 2011-12-22
EP2424897B1 (en) 2015-01-07
NZ596712A (en) 2013-10-25
CL2011002664A1 (es) 2012-12-14
US20130174288A1 (en) 2013-07-04
US20160031995A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
BRPI1011540A2 (pt) anticorpos anticxcr4 para o tratamento de of hiv
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
BRPI0815134A2 (pt) Processo para a preparação de olmesartana medoxomila
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
BRPI0613859A8 (pt) compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0817242A8 (pt) compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BR112016006151A2 (pt) imidazopiridazinas úteis como inibidores da via de sinalização do par-2
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.